Straumann (STMN.SW, SIX) CHF96.60 on 16 Feb 2026: earnings on 18 Feb could shift valuation

STMN.SW stock trades at CHF96.60 as Swiss markets close on 16 Feb 2026, with Straumann Holding AG due to report results on 18 Feb 2026. Investors will watch revenue mix and margins for signs the recovery in implant demand is sustainable. Straumann (STMN.SW) has a market capitalisation near CHF15.40 billion and a trailing EPS of 2.69. Volume today was 334,290 shares, below the 90-day average of 399,670.

STMN.SW stock: earnings timetable and what to watch

Straumann reports earnings on 18 Feb 2026; this is the primary catalyst for STMN.SW stock near-term. Investors will focus on organic revenue, growth in ClearCorrect aligners, and margin guidance.

Analysts will also parse regional recovery, inventory digestion, and any update on pricing or FX. Straumann previously flagged margin pressure, so EBIT margin and free cash flow will determine market reaction.

STMN.SW stock: recent price action and liquidity

The share price closed at CHF96.60, down 0.80 points or -0.82% on the day, with a range of CHF94.62–98.00. Trading volume was 334,290 vs average 399,670, showing light participation.

Year high is CHF134.45 and year low is CHF83.10, which frames current upside and downside for traders and investors in Switzerland on the SIX exchange.

STMN.SW stock: fundamentals and valuation

Straumann shows EPS 2.69 and a reported PE of 35.91, above the healthcare subgroup average PE 33.64, signalling a premium. Key ratios include book value per share 12.97, dividend per share 0.95, and a dividend yield near 0.98%.

Balance sheet strength is visible: debt to equity ~0.20 and current ratio 1.64, while free cash flow per share is 2.21. High price-to-free-cash-flow (44.21) highlights valuation sensitivity to earnings surprises.

Meyka AI grade and forecast for STMN.SW stock

Meyka AI rates STMN.SW with a score out of 100: 76.15 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a yearly price of CHF97.66, implying +1.10% from today’s CHF96.60. The monthly model points to CHF82.88, implying -14.21% near-term downside. Forecasts are model-based projections and not guarantees.

STMN.SW stock: technicals and trading signals

Momentum indicators are neutral: RSI 51.53 and MACD histogram 0.34, suggesting no strong trend. Bollinger middle band is CHF96.49 with upper CHF101.72 and lower CHF91.26.

ATR is 2.79, indicating moderate daily volatility. Traders may watch a break above CHF101.72 for trend resumption, or a move below CHF91.26 for downside confirmation.

STMN.SW stock: risks and opportunities ahead of earnings

Key risks ahead of the report include a weaker-than-expected implant demand, margin compression from input costs, and slower ClearCorrect growth. Currency swings could also pressure reported Swiss franc results.

Opportunities include accelerated digital dental adoption, margin recovery from cost controls, and upside from international expansion. A clear beat on margins would likely lift STMN.SW stock quickly.

Final Thoughts

Key takeaways for STMN.SW stock: Straumann closes at CHF96.60 on 16 Feb 2026, with an earnings release on 18 Feb 2026 as the immediate catalyst. Financials show EPS 2.69, PE 35.91, and free cash flow per share 2.21, leaving valuation sensitive to profit surprises. Meyka AI’s grade is B+ (76.15) and the model projects a yearly target of CHF97.66, an implied upside of +1.10% from today. For traders, the Bollinger range CHF91.26–101.72 sets technical thresholds. For investors, consider a base 12-month price target CHF100.00, conservative CHF90.00, and bullish CHF120.00, reflecting scenario-driven outcomes. Remember, Meyka AI is an AI-powered market analysis platform; forecasts and grades are model outputs and not guarantees or personalised advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.